Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R8EU
|
||||
| Former ID |
DIB019882
|
||||
| Drug Name |
FTIDC
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [541504] | ||
| Formula |
C18H23FN6O
|
||||
| InChI |
InChI=1S/C18H23FN6O/c1-12(2)23(4)18(26)24-10-7-14(8-11-24)16-13(3)25(22-21-16)15-6-5-9-20-17(15)19/h5-7,9,12H,8,10-11H2,1-4H3
|
||||
| InChIKey |
CJTLKLBSIFQKNT-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropicglutamate receptor 1 | Target Info | Modulator (allosteric modulator) | [528732] | |
| References | |||||
| Ref 528732 | Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.